FTC Homeopathic Meeting Features Tort Attorney, Commissioner Critical Of Enforcement
This article was originally published in The Tan Sheet
Executive Summary
The event agenda includes eight industry executives, researchers, attorneys and FDA officials who made presentations or were agency panel members at FDA’s public hearing in April. Commissioner Maureen Ohlhausen, who has advocated allowing firms regulatory room to advertise, speaks to open the meeting.
You may also be interested in...
FTC Could Open Arms For Health Claim Science In Regulatory Review
FTC is implementing Trump administration directives on "eliminating wasteful, unnecessary regulations and processes," but attempting to reduce regulated industries' compliance burden is not the same as slowing FTC enforcement against false and misleading advertising, attorneys say.
FDA Examination Of Homeopathic Regulation Looks Beyond Safety History
CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. During a two-day public hearing, agency officials question stakeholders about trials, labeling and how well consumers understand their products.
FTC’s Stern POM Opinion Expands Disease Claim Findings
The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.